With an ambitious vision for growth, advancing the organization mission, and deepening connection to the local community, CvilleBioHub announces the recent appointments of three board members to a newly expanded...
Next Gen Nutrition Investment Fund, LP (NGN) is pleased to announce a strategic investment in Bonumose LLC, which has developed and patented an enzymatic technology platform for continuous production of...
Charlottesville leaders focus on bolstering the regional entrepreneurial ecosystem in the biotech sector through new collaboration
As part of the collaboration, CAV Angels will engage early in the review process with CvilleBioHub to support founders and early stage concepts to streamline the pathway for funding resources.
UVA has selected 14 promising biomedical research projects to receive funding from the Ivy Foundation COVID-19 Translational Research Fund.
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
This award will enable HemoShear to have more frequent interactions with the FDA, as well as eligibility for accelerated approval, priority review, and rolling submission of a new drug application.
HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia
The FDA has cleared HemoShear to begin a phase 2 clinical study of oral drug HST5040 for treating patients with rare metabolic diseases MMA and PA.
Bryan Berger, an associate professor of chemical engineering at UVA and CEO of Lytos Tech, received funding for research related to fighting the COVID-19 pandemic.
Governor Northam Announces $2.48 Million to Support New Research Commercialization in Emerging Technology Sectors
The new Commonwealth Research Commercialization Fund, administered by Virginia’s Center for Innovative Technology (CIT), announces awards, including Charlottesville BioHub companies AgroSpheres, Babylon Microfarms and KeViRx.
The selected startups will conduct research and development activities at the Donald Danforth Plant Science Center in St. Louis, a program partner and the world’s largest independent plant science institute.
A few years ago, a University of Virginia football player believed his injured hamstring had healed sufficiently and that he was ready to return to action.
Virginia Based AMPEL BioSolutions' Technology Predicts Severity of Illness in COVID19 Patients and Identifies Treatments
AMPEL BioSolutions announces genomic analysis and findings that could improve treatment of COVID19 patients with approved drugs such as Embrel and Stelara.